FLT3 and acute myeloid leukemia: In 2021, Yang group obtained a series of PROTACs based on the binding model of Dovitinib and FLT3.169 After screening in vitro antiproliferative activity, it was found that the degrader 101 (Fig. 24) and 102 (Fig. 24) had significant antiproliferative effects on MOLM-13 and MV4-11 cells (FLT3-ITD-positive AML cells), which were better than the inhibitor Dovitinib.